Coherus Oncology Inc - Nakit Akışı (NASDAQ:CHRS) | MetaTrader

Tam grafiği aç Full chart

Financials

Genel Bakış Tablolar İstatistikler

Çeyreklik Yıllık

İşletme faaliyetlerinden elde edilen nakit 154.15 M-37.43 M-241.12 M-174.88 M-20.44 M-138.51 M -170.57 M Yatırım faaliyetlerinden elde edilen nakit -14.4 M-138.41 M-166.85 M144.64 M230.32 M375.09 M 423.23 M Finansman faaliyetlerinden elde edilen nakit 223.95 M51.88 M54.33 M69.6 M-186.97 M-273.7 M -219.85 M Serbest nakit akışı 154.15 M-37.43 M-241.12 M-174.88 M-20.44 M-138.51 M -170.57 M

Haberler

Coherus Oncology: Setting Up For Important Readouts In Mid-2026 (NASDAQ:CHRS)

Coherus BioSciences’in 1Ç 2026 geliri beklentilerin altında

Coherus Oncology (CHRS) Reports Q1 Loss, Lags Revenue Estimates

Are Medical Stocks Lagging AnaptysBio (ANAB) This Year?

Is Brookdale Senior Living (BKD) Outperforming Other Medical Stocks This Year?

Is Biodesix (BDSX) Stock Outpacing Its Medical Peers This Year?

Coherus BioSciences Citizens Konferansı’nda: Stratejik Onkoloji Dönüşümü

Coherus BioSciences at The Citizens Conference: Strategic Oncology Shift

Oppenheimer, Coherus Biosciences için Outperform notunu tekrarladı

Oppenheimer reiterates Coherus Biosciences stock rating at Outperform

Coherus Oncology, Inc. (CHRS) Q4 2025 Earnings Call Transcript

Coherus Oncology (CHRS) Reports Q4 Loss, Misses Revenue Estimates